TRENTON, N.J., Shawwal 9, 1436, Jul 25, 2015, SPA -- An experimental drug for one of the hardest-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options — all much more effective but extremely costly for patients with the liver-destroying virus. Daklinza, developed by New York-based Bristol-Myers Squibb Co., is the first drug approved to treat genotype 3, the second-most-common form. About 10 percent of Americans with hepatitis C have genotype 3, AP reported. -- SPA 00:42 LOCAL TIME 21:42 GMT www.spa.gov.sa/w